Combination Therapies With Adagrasib in Patients With Advanced NSCLC With KRAS G12C Mutation
Clinical trial NCT05609578 · ACTIVE_NOT_RECRUITING
Trial details
- NCT number
- NCT05609578
- Sponsor
- Mirati Therapeutics Inc.
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2022-11-22
- Primary completion
- 2026-09-30
- Enrollment
- 90
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.